Clinical Trials Browser

Phase 1 × Completed × itacitinib × Clear all

B-cell Malignancies

NCT03755414 2025-04-06

Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

LymphoidMyeloidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03989466 2024-10-10

Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia

Phase 1 Completed

15 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Prolymphocytic, T-Cell

NCT02646748 2022-03-31

Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors

Phase 1 Completed

159 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Clinical Trials

Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies

Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia

Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors